Eli Lilly's tirzepatide shows a 94% reduction in diabetes risk and significant weight loss in adults with pre-diabetes and obesity, according to a three-year study.

Discover the unexpected U.S. state leading the surge in GLP-1 weight loss drug usage, driven by celebrity endorsements and healthcare innovations, with significant economic implications.

Explore the shift in GLP-1 drug use as a growing number of non-diabetics turn to these medications for weight loss. Understand the new trends and their impact on diabetes care.

New analysis reveals 85% of individuals stop using GLP-1 drugs for weight loss after two years. Learn about adherence trends and the role of fitness centers like Equinox and MIORA by Life Time in obesity management.

Discover how Ozempic and other GLP-1 agonists may reduce the risk of obesity-associated cancers in a recent study of obese patients. Learn more about the potential cancer-preventive effects of these diabetes medications.

Discover how GLP-1 agonist drugs are becoming increasingly popular among adults, with 43% now using them for weight loss and chronic conditions. Learn about the rising awareness and affordability challenges revealed in the latest poll.

Discover how Nestlé Health Science is addressing the growing GLP-1 medication market with their new nutrition platform and Vital Pursuit food line, designed to support weight management and wellness.

Discover Ro's new GLP-1 Supply Tracker, providing real-time insights into GLP-1 drug shortages. Learn how this tool helps manage medication availability as demand for weight loss drugs rises.

New research from the University of Aberdeen reveals how physical fitness influences the body's metabolism of saturated fat. Discover how exercise impacts fat utilization and improves overall metabolic health.

Discover strategies to mitigate the high costs of discontinuing GLP-1 medications. Learn how employers can plan for effective weight management and ensure long-term adherence.

Discover the latest on Peloton's leadership changes and workforce adjustments, including CEO Barry McCarthy's transition to a strategic advisor and a 15% reduction in staff due to decreased demand for fitness equipment post-pandemic.

Explore the latest study on obesity treatments in the Obesity journal, analyzing the effectiveness of traditional diets, GLP-1 receptor agonists like semaglutide and tirzepatide, and surgical options such as Roux-en-Y gastric bypass. Learn how these interventions impact weight-loss plateaus.

Life Time (NYSE: LTH) appoints James LaValle as Chief Science Officer to lead MIORA, a new longevity and performance program, with its first clinic at Life Time Target Center in Minneapolis. Learn more about LaValle's role and MIORA’s innovative health services.

Discover how MyFitnessPal is revolutionizing weight loss support with new tools for GLP-1 medication users, enhancing tracking and nutrition management to promote sustainable health improvements. Explore our comprehensive approach to integrating fitness with medication management.

Explore the intricacies of the GLP-1 supplement trend with a focus on consumer health, informed choices, and the importance of professional guidance in the pursuit of wellness.

Explore the Obesity Bill of Rights: An initiative aimed at enhancing access to quality obesity care for Americans. Learn more about this significant healthcare development.

The Ontario government is making big changes in how people can get Ozempic, a medicine mainly used for Type 2 diabetes. This shift is happening because more and more people want Ozempic, especially after celebrities like Oprah Winfrey praised it as a fantastic weight loss solution. This huge demand for Ozempic has caused a shortage in supply. Sadly, it means that people with Type 2 diabetes are finding it harder to get this medicine through the Ontario Drug Benefit (ODB) program.